The Phase 1 / 2 trial of DSP107 from Israel’s KAHR Medical (see here previously) has commenced and will now be expanded to include blood cancer patients in addition to solid tumors. KAHR has received an additional investment of $5 million to fund the enlarged trial.
Cancer treatment trial extended
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.